Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 132 participants.
Also called NCT06126380
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 132 participants
- Sponsor
- Registry
-
NCT06126380
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Brazil, Canada, France, Germany, Spain, United Kingdom
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT06126380. Non-randomized; no masking; primary purpose treatment. Start 2023-10-25 (actual); primary completion 2029-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
- Condition
- Kidney Transplant Rejection
- Intervention (Drug)
- AT-1501
- Intervention (Drug)
- Tacrolimus
- Lead sponsor
- Eledon Pharmaceuticals
Record details
- Record id
cardio:ct-nct06126380- Content hash
6ac94a61b7dd0a256e3057fb5e7dfe8e9987ab9b0bdb785de2f9eacfc0d97888